On April 16, 2014, Pharmaceutical giant, Inovio Pharmaceuticals Inc (NYSEMKT:INO), is scaling up its leadership restructuring process having announced the appointment of E.J.Brandreth as the company’s new Vice President for quality. Inovio Pharmaceuticals Inc (NYSEMKT:INO), shares after opening at $2.40 moved to $2.59 on last trade day and at the end of the day closed at $2.56. Company price to sales ratio in past twelve months was calculated as 45.54 and price to cash ratio as 11.69. Inovio Pharmaceuticals Inc (NYSEMKT:INO), showed a positive weekly performance of 6.22%.
Molecular diagnostic testing and genetics company, Sequenom, Inc. (NASDAQ:SQNM), is surging in early morning trading after beating estimates with its first quarter results, having posted record revenues. Sequenom, Inc. (NASDAQ:SQNM), shares advanced 8.57% in last trading session and ended the day on $2.90. Sequenom, Inc. (NASDAQ:SQNM), return on equity ratio is recorded as 698.50% and its return on assets is -58.80%. Sequenom, Inc. (NASDAQ:SQNM), yearly performance is -19.22%.
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced financial results for the first quarter ended March 31, 2014. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), shares moved down 4.33% in last trading session and was closed at $57.70, while trading in range of $ 55.50 – 60.20. Royal Bancshares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), year to date (YTD) performance is -17.98%.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, reported financial results for the 3 months ended March 31, 2014, and also provided an overview of recent accomplishments and upcoming milestones for its clinical development programs. CytRx Corporation (NASDAQ:CYTR), weekly performance is 6.62%. On last trading day company shares ended up $3.22. CytRx Corporation (NASDAQ:CYTR), distance from 50-day simple moving average (SMA50) is -22.08%. Analysts mean target Price for the company is $11.00.